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1. Introduction 
Long-term testosterone deficiency related to age may adversely affect health, anatomy and 
physiology of man. The implementation of testosterone boost therapy only at the time, 
when for many years, as the result of testosterone deficiency, irreversible anatomical 
changes have occurred, is clearly too late. Age-related progressive decrease in testosterone 
serum concentration levels causes anatomical and functional abnormalities. It is the cause of 
lipid disorders; it excarberates type-2 diabetes, it is also the common cause of cardiovascular 
diseases. It contributes to other health problems such as atherosclerosis, hypertension, 
osteoporosis and obesity and it manifests itself by decreased libido and potency. There is 
also a strong relationship between age-related decrease in testosterone and Parkinson's 
disease and Alzheimer's disease. Benign prostatic hyperplasia (BPH) and carcinoma of the 
prostate are closely associated with testosterone deficiency and comedo-carcinoma — the 
most malignant form of prostate cancer — is directly proportional to the decrease in serum 
testosterone. A good therapy for increasing testosterone serum levels can reverse the 
problems associated with aging such as type-2 diabetes, sexual dysfunction, osteoporosis, 
hyper-lipidemia and ischemic heart disease. It can even reverse symptoms of Parkinson's 
disease. Using synthetic testosterone is often recommended in the treatment of testosterone 
deficiency. Unfortunately, synthetic testosterone can cause side effects such as infertility and 
a long-term use of testosterone may also lead to irreversible testicular atrophy. Therefore, 
patients receiving long-term testosterone therapy are all dependent on adequate doses of 
synthetic testosterone until the end of their lives. Meanwhile, intramuscular administration 
of hCG to stimulate the endogenous testosterone synthesis, has been known since the 1950s. 
The induction of endogenous testosterone production by hCG has been effective in all age 
groups while being safe at the same time. In this paper, the author presents problems caused 
by testosterone deficiency and outlines the possibility of the treatment, which increases the 
induction of testosterone endosynthesis by hCG. It has not yet been determined how to 
diagnose testosterone deficiency. The age-related serum testosterone concentration reference 
range has not been established yet either. The paper presents the first attempt to establish 
international standards for testosterone serum concentration levels in different age groups. 
2. Late-onset hypogonadism  
Late-onset hypogonadism (LOH) is a testosterone deficiency syndrome resulting in the aging 
process. LOH leads to metabolic disorders and functional or anatomical abnormalities. It is 
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now beyond dispute that, as testosterone deficit increases with age, it adversely affects the 
function of multiple organ systems. Therefore the implementation of appropriate strategies to 
increase testosterone levels only when as a result of testosterone deficiency irreversible 
anatomical changes have occurred, is clearly too late, which operates to the detriment of men. 
Recent studies suggest that there are large numbers of men in the community whose 
testosterone deficiency is neither being diagnosed nor treated (Trinick et al., 2011). 
Testosterone exerts influence on multiple life processes such as blood cell production, bone 
formation, lipid metabolism, protein metabolism, carbohydrate metabolism, liver function, 
and spermiogenesis (Gooren, 2000). This can affect the structure and function of many organs 
in human body. They include skin, hair, muscle, brain and bones. It also has a significant effect 
on fertility and sexual behaviour. Testosterone plays a very important role in a man's life. At 
the mitochondrial level of each single cell it is the catalyst for protein synthesis. It has an effect 
on the brain's function, and thus determines the physical and sexual condition. It increases 
libido and improves sexual potency. It stimulates the immune system and affects multiple 
metabolic processes. It reduces body fat accumulation. It can affect muscle mass and strength. 
It increases bone mass and accelerates wound healing. Testosterone is responsible for our 
memory processes. Computer memory circuits are manufactured using metal arranged on 
silicon. In the process of human memory, proteins are involved. The testosterone that catalyzes 
the synthesis of various proteins is also a catalyst for storage protein synthesis. Protein 
synthesis becomes less efficient with age, proteins formed are unstable. Their decay means that 
an old man remembers what was years ago and cannot remember what just happened. In the 
literature, there have been isolated reports about the role of testosterone in the aetiology of 
Alzheimer's disease (Hogervorst, 2004).  
Testosterone also aids in immune system protein synthesis, which protects us against 
infection. Hormone intake in pregnant women during the first trimester of pregnancy 
significantly affects hormone balance in young men. Although hormone therapy allows the 
woman to keep her pregnancy from failing, it is also essential for organogenesis, and in 
particular for the reproductive organs of male foetuses. According to the definition in 
Standards of Endocrinology, “Testosterone deficit disorder manifests itself in a decrease in 
libido and potency, in constant fatigue, in deterioration of mood and in sleep quality, in 
nervousness, in hot flushes, in low testosterone, and in elevated serum gonadotropin 
concentrations” (Zgliczyński & Zgliczyński, 2002). However, according to the definition 
provided by ISSAM, the International Society of Andrology (ISA) and the European 
Association of Urology (EAU), it is “a clinical and biochemical syndrome associated with 
advancing age, characterized by typical symptoms and a deficiency in serum testosterone 
levels. It can cause a significant deterioration in over-all quality of life and adversely affect 
the function of many different organs and systems” (Nieschlag, et al., 2005). It is now 
beyond dispute that, as testosterone deficit increases with age, it adversely affects the 
function of multiple organ systems. Previously adopted minimum standard testosterone 
levels, at which there has been best evidence for treatment, are far too low. The 
implementation of the therapy to boost testosterone levels at the time when for many years, 
as a result of testosterone deficiency, irreversible anatomical changes have occurred, is 
clearly too late, which operates to the detriment of men (Gomuła & Rabijewski, 2010). 
According to Tenover, if we consider the norm based on the level of total testosterone,  in a 
group of 55-year-old men, 20% of them will be hypogonadal; and in the same group of men, 
when we adopt a standard based on the level of bio-available testosterone, hypogonadism will 
be diagnosed in half of them (Tenover, 1997). Cross-sectional studies have shown that, since 
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this is associated with a simultaneous increase of SHBG levels, bioavailable testosterone may 
decline more significantly than apparent total testosterone (Snyder, 2001, Vermeulen, 2001). 
Only the testosterone circulating in the body which is not bound to SHBG is biologically active 
in the target organs. Therefore the measurement of bioavailable testosterone levels more 
accurately reflects a patient's clinical status than the measurement of total testosterone levels. 
The study of 810 men aged 24-90 years showed a strong correlation between age and a 
decrease in bioavailable testosterone level and in estradiol level (r =- 0.52). It was still strong 
when other variables were taken into account such as alcohol intake, BMI, smoking, caffeine 
intake, and diabetes (Ferrini & Barrett-Connor, 1998). Also significant but weaker (r=- 0.13) 
correlations were found between age and total testosterone and estradiol levels. Both the 
decreased testosterone production and its increased conversion can explain a reduction in total 
testosterone levels, while age-related increase in sex hormone binding capacity can cause 
reduced biologically available testosterone production. The correlation between age and the 
level of bioavailable and of total estradiol in men has not been studied previously. Bioavailable 
estradiol levels might decrease due to a decline in levels of testosterone, which is the main 
substrate for male estradiol production. It also contributes to an increase of SHBG with age. In 
one of the largest studies, which involved 2,623 men aged 65 and over, enjoying good health, 
levels of free and bioavailable testosterone and estradiol levels correlated with each other 
(Orwoll, et al. 2006). Higher age, higher BMI, and worse health status were associated with 
slightly lower total testosterone levels. The concentration of SHBG rose with age. The decrease 
in testosterone levels fell approximately 10% for 10 years. Many old men still had testosterone 
levels established for young men. However, it is unknown which level of testosterone is 
sufficient for an elderly person and for that person’s specific tissues (i.e. muscles, bones, and 
nervous system). The number of androgen binding sites in the hippocampus and the number 
of the layers of the skin tissues that cover the penis increase with age (Hijazi & Cunningham, 
2005). Testosterone production peaks at age 20 and then begins a gradual decline, usually 
giving rise to the first symptoms after the age of 50. In a group of men aged 80, the level of free 
testosterone is half of what they had when they were younger (Vermeulen, et al., 1996).  
2.1 Hypogonadism – Primary, secondary, LOH 
Classic categorization of hypogonadism differentiates its primary and secondary types. In 
the case of primary hypogonadism, testicles are unable to synthesize estosterone, while in 
case of secondary hypogonadism low testosterone is caused by pituitary insufficiency. Until 
present from the pathophysiology point of view, LOH has been regarded as a mixed type of 
hypogonadism conditioned by the changes undergoing both in gonads (component of 
primary hypogonadism) and on the level of central controllers of testicular functions; 
hypothalamus and pituitary (components of secondary hypogonadism). Hypothalamus and 
pituitary regulate, on the basis of feedback, functions of Leydig cells in testicles. 
Gonadotrophin-releasing hormone is a trophin hypothalamus hormone relative to the 
Leydig cells. Its effect on pituitary results in the synthesis of luteinizing hormone (LH) and 
folicule stimulating hormone (FSH) in gonadotrophin cells. Gonadotrophin LH stimulates 
the synthesis of testosterone through the Leydig cells in testicle. With age, pulsating 
secretion of LH becomes disturbed. Pulses become more scarce (decreased frequency), of 
lower amplitude and their duration extends. The result is an  increase of LH concentration 
with age. If LH concentration increases with age, thus pituitary insufficiency, i.e. secondary 
hypogonadism, does not exist and testicles retain their capability of high endosynthesis of 
testosterone, hence in case of LOH features of primary or of secondary hypogonadism are 
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non-existent. It has been acknowledged that testicle stimulation with hCG does not cause 
any substantial, sufficient increase of endosynthesis of testosterone. And here lies the 
fundamental error – the statement that hCG does not result in any substantial increase of 
testosterone endosynthesis is untrue!!! Therapy based on hCG allows doubling the 
concentration of testosterone, which in over 90% of those treated enables restoring a normal 
hormone condition. I base my statement on over a 10-year long observation of 1200 patients 
I treated with hCG to induce endosynthesis of testosterone.  
Secretion of GnRH is distorted as well. Hypothalamus response to change of LH pulse 
nature and to lowered secretion of androgens is incommensurate. The phenomenon is 
referred to as dysregulation of hypothalamus pulse generator. The reasons for alternations 
of pulsating secretion of GnRH and LH are unclear, however of importance are genetic 
factors and backward changes in gonadotrophin cells and in reflective microcirculation on 
hypothalamus and pituitary axis (Snyder, et al., 2000). Ferrini, Wang, Hakim et al. have 
established that changes in functioning of hypothalamus and pituitary may not be the major 
cause of gonads dysfunctions in men (Ferrini, et al., 2001). They have found evidence for a 
substantial increase of hypothalamus and pituitary apoptosis, two changes clarifying 
development of hypogonadism at old age. Until now it was believed that together with 
hypothalamus and pituitary dysfunction gonadal backward changes played an important role 
in etiopathogenesis of gonads. The process of decreasing testosterone synthesis starts 
approximately at the age of 35-40 years and is of extreme individual variability. Changes 
within testicles are noted for progressive decrease of the number of Leydig cells and 
deterioration of Sertoli cells functions and as a result decrease of secretion of inhibin, impaired 
micro-circulation and blood-supply of testicle cells and backward changes within perivascular 
parenchyma (Deslypere & Vermulen, 1984, Snyder, 2001). From the analysis of own material it 
is considered that to-date views on TDS aetiology are unfounded. As it has been demonstrated 
in the material consisting of 908 men treated with induction of endosynthesis, it is possible 
with every age group, but it decreas in terms of physiology with age. Nevertheless, the 
capability of efficient endosynthesis is retained until advanced years, which contradicts views 
of atrophy of Leydig cells functions. From a clinical point of view, LOH resembles pathology 
of incorrect LH bioactivity described in men of 47XY karyotype who after adolescence 
undergo hypogonadism with decrease of testosterone and increase of LH concentration. These 
patients demonstrate correct gonads response to LH stimulation. It has been acknowledged 
that in these cases LH bioactivity is decreased, while immunoreactivity is normal. It results 
from glutamine changing into arginine in position 54 of beta chains.  
Currently, it is not possible to define explicitly the aetiologic factor of LOH leading to 
testosterone shortfall. Testosterone shortfall results in metabolic syndrome causing 
disorders of many bodily functions such as memory disorders, difficulties with falling 
asleep, excessive nervousness, deterioration of ability to associate and concentrate, heat 
waves, depression tendencies, vertigo and headache, fall of strength and muscle bulk, as 
well as numerous cardiovascular system complaints. Testosterone concentration drop leads 
to lipid disorders and diabetes type 2.  
2.2 Andropause, ADAM, PADAM, LOH, TDS 
The concept of “male menopause” has been known since 1960s (Wang, et al., 1996) yet until 
today it has not been unambiguously defined. The names of the clinical state caused by 
testosterone shortfall have changed many times over decades which explicitly proves lack of 
firm facts based on indisputable ground. Names of andropause, sarcopenia, viropause were 
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followed by andropause, (Morley & Perry, 2003) which stayed in medicine for good. Many 
learned societies with the term of andropause in the centre were established around the 
world. However the term of andropause is erroneous by definition. Such a phenomenon as 
pause, break in production of testosterone with men does not exist. Since a pause is a stage 
of an activity as discontinuation and a pause (a break) is followed by return to the activity 
from before the pause. At the end of previous century notions of Androgen Deficiency in 
Aging Male or Androgen Deficiency in Adult Male /ADAM/ (Carruthers, 2004) came to being. 
It must be emphasized that an adult man is aged between 20-25 years, while an aging man 
according to International Society for the Study of the Aging Male (ISSAM) is a gentleman above 
60-65 (Carruthers, 2004). This is where the dilemma arises, does the testosterone shortfall 
issue concern exclusively elder men or younger, adult men? Testosterone shortfall has 
earned yet another name— PADAM (partial androgen deficiency in aging male), which defines 
the testosterone shortfall in a not sufficiently explicit manner. The concept lacks 
specification of boarder testosterone concentration and thus the value according to which a 
shortfall can be recognized. Therefore the term PADAM should not be used at all. What 
does partial shortfall mean? No accounting system recognizes partial deficit, it either exists 
or does not. Can a woman be partially pregnant? Another term was established; secondary 
or late onset hypogonadism but it still did not represent the core of the problem (Morales, et 
al., 2006). As clinical symptoms of androgen shortfall manifest themselves already at the 
break of forth and fifth decade (Mosby, 1998) (35–45 years), i.e. in the first half of life, can it 
be said that hypogonadism appears late? The latest name of the disease, which so far has not 
been explicitly defined, is testosterone deficiency syndrome /TDS / (Morales, et al., 2006) — 
currently a fashionable term. Yet science and fashion follow totally different criteria. What 
counts in fashion is a one-season success, while in science exact, indisputable facts forming a 
solid basis for many years should be essecial. In the meantime, testosterone shortfall, an 
unfavourable phenomenon leading to various metabolic disorders or issue pathologies, has 
not been named a disease until now.  
2.3 Late - onset hypogonadism and age related testosterone levels 
Many studies have now demonstrated that as men age, their serum testosterone 
concentrations fall at an average rate of 0.8%–1% per year (Feldman, et al., 2002, Kaufmann 
& Vermeulen, 2005). Concurrently, free and bioavailable testosterone levels fall by 2% per 
year (Kaufmann & Vermeulen, 2005). Obesity, alcohol abuse, diabetes, hypertension, heart 
disease, cancer and ulcers have intensified the negative impact (Harman, et al., 2001).  
Therefore, and also due to an increase in the concentrations of carrier proteins, significantly 
decreased testosterone levels characterise approximately 8% of men of 40-60 and 20% men 
of 60-80 (Kaufmann & Vermeulen, 2005). The question arises: how to measure the decrease 
in testosterone levels during the life of a man? By the hormonal status of young people 
today? The hormonal status of their fathers? What was the hormonal status of their 
grandparents in their youth, since testosterone levels in men over age 70 often reach the 
upper range of the standard? And another question: what was the testosterone level of a 30-
year-old man, whose level now, at 70, is more than 35 nmol/L? 
Standard testosterone levels vary in different analytical laboratories. In American research 
laboratories alone, the lower limit of normal testosterone level ranges from 4.5 to 15.6 
nmol/L – 350% difference (Lazarou, et al., 2006) 
The effects of an objectively measurable drop in testosterone levels may also vary. Researchers 
wonder if it would be most appropriate to establish separate ranges of normal testosterone 
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levels for the young and for the old (Lunenfeld & Gooren, 2002). It is also unknown whether 
the plasma testosterone threshold values vary with age. There is preliminary evidence that the 
threshold value necessary for the proper functioning and for the proper effects of testosterone 
also increases with age (Schiavi, et al., 1993). Bancroft hypothesizes that the threshold required 
for the behavioral effects of testosterone increases with age (Bancroft, 1989). Although many 
older men have testosterone levels within the normal range, their levels may not be sufficient 
for normal sexual functioning. Probably organ sensitivity to androgens is not the same for the 
young and for the old. Schiavi reported that nocturnal erections are androgen-dependent and 
are disrupted in healthy elderly men who do not meet the criteria for hypogonadism, which 
seems to confirm Bancroft's hypothesis  (Bancroft, 1989, Schiavi, et al. (1993). Based on the 
analysis of the material provided by 1267 men of 20-89, together with the material provided by 
908 men under treatment, standard levels of testosterone have been age-determined (Gomuła 
& Rabijewski, 2010). Among the respondents between 20-29, the average level of testosterone 
was 21.99 nmol/L; among the respondents between 30-39 – 21.91 nmol/L among the 
respondents between 40-49 – 19.18 nmol / L; among the respondents between 40-49 - 19.18 
nmol/L; among the respondents between 50-59 – 17.74 nmol/L; among the respondents 
between 60-69 – 15.94 nmol/L among the respondents between 70-79 – 17.66 nmol/:L and 
among the respondents between 80-89 – 16.65 nmol/l. The standard testosterone levels in 
individual age groups (minimum and maximum, average level, standard deviations and 
medians) are shown in Table 1.  
 
Age/min-max, 
median,average,SD 
n, Testosterone 
in nmol/L 
Age/min-max, 
median,average,SD 
n, Testosterone 
in nmol/L 
20–29 years n = 78 60–69 years n = 281 
Min., max. 4.64; 49.10 Min., max. 2; 40.40 
Average (SD) 21.99 (9.33) Average (SD) 15.94 (6.68) 
Median (25%, 75%) 19.75 (15.40; 26.20) Median (25%, 75%) 15 (11.30; 19.70) 
30–39 years n = 102 70–79 years n = 213 
Min., max. 8.90; 46.80 Min., max. 2.71; 45.60 
Average (SD) 21.91 (8.18) Average (SD) 17.66 (7.87) 
Median (25%, 75%) 21.70 (15.80; 25.20) Median (25%, 75%) 16.10 (12.70; 21.30) 
40–49 years n = 176 80–89 years n = 50 
Min., max. 3.40; 47.20 Min., max. 3.70; 38.80 
Average (SD) 19.18 (8.92) Average (SD) 16.65 (7.55) 
Median (25%, 75%) 17 (12.6; 24.30) Median (25%, 75%) 15.75 (12; 20.60) 
50–59 years n = 367  
Min., max. 3.10; 53.50 
Average (SD) 17.74 (8.01) 
Median (25%, 75%) 16.20 (12.10; 21.70) 
n - number of patients in the age group ,  SD - standard deviation 
Table 1. Testosterone levels of 1267 men in different age groups 
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The evaluation of 1267 men aged 20-89 years has found that the average testosterone level in 
all age groups is higher than 12 nmol/L – what is shown in Fig. 1. 
 
 
Fig. 1. The average testosterone levels of 1267 men in different age groups. The horizontal 
line on the graph represents an accepted lower limit of normal testosterone level 12 nmol/L 
/according to the International Society for the Study of the Aging Male/ (Lunenfeld, B. Et 
al., 2005, Nieschlag, et al., 2005). If we assume that the standard testosterone level is higher 
than 12 nmol/L, in the age group 20-29 years testosterone deficit has been found in 11.5% of 
those examined. In the age group 30-39 years the deficit has been found in 5.9% of those 
examined. In the age group 40-49 years – in 21% of those examined; in the age group 50-59 
years – in 24% of those examined; in the age group 60-69 years – in 27.8%; in the age group 
70-79 years – in 20.6%; and in the age group 80-89 years – in 24% of those examined. 
Testosterone deficiency (serum testosterone concentrations below 12 nmol/L) in different 
age groups is shown in Table 2. 
 
Age N pts % 
20–29 9/78 11.5% 
30–39 6/102 5.9% 
40–49 37/176 21% 
50–59 88/367 24% 
60–69 78/281 27.8% 
70–79 44/213 20.6% 
80–89 12/50 24% 
Table 2. Testosterone deficiency in different age groups. 
On the basis of the TDI ratio, testosterone deficiency has been found in 49.55% of those in 
the study group. The smaller number of patients who had TDI determined is due to the 
absence of the ratio of LH for 48 out of 1267 patients. Summary of parameters to provide a 
basic index of the Andropause status for 1219 patients is shown in Table 3. 
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Parameter     n = 1219 pts 
T (ng/mL) 
Min., max. =  0.58; 15.41 
Average (SD)= 5.22 (2.33) 
Median (25%, 75%) = 4.78 (3.59; 6.48) 
LH  (IU/L) 
Min., max. = 0.2; 47 
Average (SD) = 5.8 (4.6) 
Median (25%, 75%) = 4.8 (3.3; 6.7) 
T/LH 
Min., max. = 0.02; 41.76 
Average (SD) = 1.36 (1.67) 
Median (25%, 75%) = 1 (0.63; 1.61) 
TDI < 1 = 604/1219 (49.55%) 
T — testosterone; LH — luteinizing hormone; SD — standard deviation; TDI —testosterone deficit index. 
Table 3. Average serum testosterone concentrations , LH and TDI 
The findings in Table 4 show, on the basis of the TDI ratio, an increased incidence of 
testosterone deficiency with age. 
 
Age TDI < 1 
20–29 21/78 (28%) 
30–39 29/101 (28.7%) 
40–49 56/165 (33.9%) 
50–59 160/355 (45.1%) 
60–69 174/271 (64.2%) 
70–79 124/197 (62.9%) 
80–89 38/47 (80.85%) 
Table 4. Testosterone deficiency in different age groups for 1219 male respondents, 
calculated on the basis of TDI. 
Two methods of assessing testosterone deficiency have been compared, based on global 
standards and on TDI. Figures 2 and 3 show the material discussed above under analysis. In 
the group of 1267 patients, there were only 274 males with serum testosterone 
concentrations levels below 12 nmol/L, which amounts to 21.62% of those examined, 
whereas, in accordance with TDI standards, 604 out of 1219 men had testosterone 
deficiency, which amounts to 49.55% of those examined. The observed difference between 
the groups is statistically significant. 
If we put on the two graphs (Figure 2 and Figure 3) the lines connecting testosterone level in 
young men when they have the highest testosterone level (i.e., 30-39 year olds), it turns out 
that the testosterone deficit estimation results in accordance with the standardised 
testosterone-below-12-nmol/l approach are different from those in accordance with TDI 
standards. As shown in Figure 2, in accordance with the most rigorous standards of serum 
testosterone concentration, men aged 60-70 years have been diagnosed with testosterone 
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Fig. 2. Testosterone levels below 12 nmol/L in relation to age.  
 
Fig. 3. TDI (Testosterone Deficit Index) in relation to age. 
deficiency, while testosterone deficiency levels have clearly been lower in the age group 70-
79 years and in the age group 80-89 years. An assessment in accordance with the 
testosterone-concentrations-below-12-nmol/L parameter exhibits significant deviations. It 
shows that, as men age, testosterone deficiency does not increase in a linear fashion. 
However, Figure 3 shows that the analysis of the same material on the basis of the 
testosterone deficiency index (TDI) demonstrates that, as men age, testosterone deficiency 
increases in a linear fashion. The study proves the effectiveness of the testosterone 
deficiency index (TDI) in assessing the degree of testosterone deficiency. On the basis of the 
TDI results and/or on the basis of a patient's clinical status, 903 of those examined were 
involved in testosterone endosynthesis induction treatment with human chorionic 
gonadotropin /hCG/ (Gould, 1951, Gomula, 2001, Gomula, 2002). Testosterone levels in 
response to hCG treatment are shown in Table 5, and graphically in Figure 4. 
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Age T-0 nmol/L T-1 nmol/L Change p 
20-29 n=44 n=44 n=44  
Min., max. 
Average (SD)  
Median (25%, 
75%) 
6.2, 49.1 
21.13 (9.7) 
19.7 (14.05, 
24.55) 
20.30, 89.10 
44.03 (13.45) 
44.05 (34.70, 
51.15) 
1.5, 42.2 
22.9 (10.9) 
23.55 (14.35, 
30.9) 
 
<0.001 
30–39 n = 63 n = 63 n = 63  
Min., max. 
Average (SD)  
Median (25%, 
75%) 
8.9; 46,8 
21.78 (8.31) 
21.7 (15.9; 24) 
20.50; 96.20 
49.62 (16.12) 
46.80 (37.60; 
60.40) 
3.9; 63.6 
27.8 (13.5) 
28.9 (16.6; 35.7) 
 
 
40–49 n = 131 n = 131 n = 131  
Min., max. 
Average (SD)  
Median (25%, 
75%) 
6.3; 46.6 
18.5 (8.47) 
16.5 (12.3; 23.6) 
11.40; 78.20 
41.72 (14.36) 
39.60 (31.60; 
50.50) 
2.1; 58.5 
23.2 (12.09) 
23.13 (13.8; 32.6) 
 
< 0.001 
50–59 n = 277 n = 277 n = 277  
Min., max. 
Average (SD)  
Median (25%, 
75%) 
3.1; 46.4 
17.14 (7.72) 
15.7 (11.9; 20.5) 
10.30; 78.30 
39.23 (12.63) 
38.50 (29.80; 
46.20) 
4.9; 62.6 
22.08 (11.7) 
20.1 (13.7; 29.6) 
 
< 0.001 
60–69 n = 205 n = 205 n = 205  
Min., max. 
Average (SD)  
Median (25%, 
75%) 
2.71; 40.4 
15.59 (6.45) 
14.4 (10.8; 19.1) 
7.50; 82.30 
34.48 (13.32) 
32.30 (24.70; 
41.90) 
4.3, 69.2 
18.9 (11,.9) 
16.8 (10.6; 25) 
 
< 0.001 
70–79 n = 154 n = 154 n = 154  
Min., max. 
Average (SD)  
Median (25%, 
75%) 
2.71; 45.6 
17.09 (7.5) 
15.15 (12.5; 19.9) 
6.80; 89 
34.08 (14.83) 
32 (23.50; 42.70) 
7.2; 59 
16.99 (13.32) 
15.6 (6.3; 24.2) 
 
< 0.001 
80–89 n = 29 n = 29 n = 29  
Min., max. 
Average (SD)  
Median (25%, 
75%) 
3.7; 27.8 
14.39 (5.43) 
14.8 (12; 17.6) 
11,50; 48,50 
27.10 (10.36) 
24.50 (18.80; 
35.40) 
4.9; 29.6 
12.72 (9.86) 
12.4 (5.4; 19) 
 
< 0.001 
Table 5. Testosterone concentration before (T-0) and during hCG treatment (T-1) in different 
age groups. 
Using Student's t-test or the Wilcoxon rank-sum test, it has been examined whether the 
testosterone concentration change is significantly different from 0. Statistically significant 
results have been achieved both for the whole group and when broken down by age group.  
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Fig. 4. Testosterone levels in different age groups before (the lower, red line) and during 
hCG treatment (the upper, green line).  
Testosterone concentrations in different age groups have risen for 908 patients under hormone 
therapy (testosterone endosynthesis induction treatment through the administration of hCG) 
by an average of between 88 percent and 128 percent. At the same time, it has been found that 
under hCG stimulation the prospects of endosynthesis decrease linearly with age in the age 
group 30-89 years. This is consistent with physiology (Figure 5). The prospects of testosterone 
endosynthesis decrease with age. The age group 30-39 years had an average 128% increase in 
testosterone levels; the age group 40-49 years – an average 126% increase in testosterone levels; 
the age group 50-59 years – an average 129% increase in testosterone levels; the age group 60-
69 years – an average 121% increase in testosterone levels; the age group 70-79 years – an 
average 99% increase in testosterone levels; the age group 80-99 years – an average 88% 
increase in testosterone levels. The full range of values of parameters determining the 
prospects of testosterone endosynthesis in different age groups has been shown in Table 5. 
 
 
Fig. 5. The prospects of testosterone endosynthesis in different age groups.  
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On the basis of the findings of the analysis of testosterone concentrations that occur 
physiologically, without treatment, during testosterone endosynthesis stimulation, it was 
decided to measure standard physiological testosterone levels correlated with age. During 
testosterone endosynthesis stimulation, testosterone concentrations obtained ade it possible 
for the patients to exhibit significantly better mood ratings, to develop improved physical 
fitness, and to increase libido and potency. The testosterone concentrations obtained also 
had the following positive impacts on blood pressure and biochemical parameters: 
normalization of the lipid profile and the reduction in HbA1c levels. Therefore, the 
testosterone concentrations obtained were adopted as normative in different age groups. 
Standard deviations of testosterone level increase while inducing testosterone endosynthesis 
by administering hCG varies by age group. This situation has been taken into account in 
measuring standard testosterone levels in different age groups. It has been assumed that 
normal testosterone levels in a particular age group is a number between the highest 
average value of testosterone while inducing testosterone endosynthesis by administering 
hCG and one standard deviation in the age group. These standards are illustrated 
graphically in Figure 6, and entered in Table 6. 
 
 
Fig. 6. The proposed standard testosterone levels for men of various age groups, based on 
the physiological capabilities caused by testosterone endosynthesis. The bottom line – the 
serum testosterone concentration in different age groups, prior to treatment; top line - 
testosterone concentrations in each age group during hCG treatment; box – proposed age-
related standard testosterone levels.  
 
Age 30–39 y 40–49 y 50–59 y 60–69 y 70–79 y 80–89 y 
T (nmol/lL) 33.5 ÷ 49.6 27.3 ÷ 41.7 26.6÷39.2 21 ÷ 34.4 19.2 ÷ 34.0 16.7 ÷ 27.1 
Table 6. Standard testosterone levels for men of various age groups, based on the analysis of 
potential testosterone endosynthesis capabilities among 908 patients treated by inducing 
testosterone endosynthesis by administration of hCG. 
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A very important question arises: if testosterone levels are so high, as the authors propose, 
are they not harmful? However, since these concentrations have been obtained by 
endosynthesis, it is obvious that they are in accordance with the body's physiological ability 
to synthesize testosterone. In addition, it has been known for more than 20 years that long-
term high-dose testosterone therapy does not give significant metabolic side effects 
(Matsumoto, 1990). The correct threshold for proper testosterone functioning and for proper 
testosterone effects also increases with age (Schiavi, et al., 1993). Therefore the proposed 
age-related standards for testosterone must be much higher than those observed previously. 
A retrospective analysis of material possessed has suggested that the hormonal balance in 
today's young men is significantly worse than the hormonal balance for their fathers when 
they were in their youth. It has been shown in fact that the total testosterone level in today's 
young men is roughly two-thirds of their fathers' testosterone level. If we draw a line in 
parallel with the decline in serum testosterone levels with age for the age group of 35 to 70 
years, and then draw it backwards, from the age of 90 to the earlier years, it will appear that 
the fathers, aged 30-35, exhibited significantly higher testosterone levels than their 
descendants at comparable ages (Fig. 7). 
 
 
Fig. 7. Concentrations of testosterone in men aged 20-90 years and the line aptly showing 
their fathers' testosterone levels in the past. 
Figure 7 shows that the concentration of testosterone in today's young men aged 30-35 is, on 
average, 23 nmol/L Concentrations of testosterone of their ancestors aged 85-89 averaged 
17.2 nmol/L Therefore, standard values in the testosterone concentration range – the 
dispersion of values previously ranging to 31 nmol/L– have now narrowed to such an 
extent that the difference in testosterone levels between younger and older men is only 5 
nmol/L i.e. 16% of normal range 10-42 nmol/L It practically means that young men now 
have testosterone levels about 35% lower than those of their ancestors. Therefore, it can be 
concluded that, on the one hand, the whole world population is aging. On the other hand, 
the biological condition of today's youth suggests that in such a metabolic-hormonal state 
the youth of today will not increase human life expectancy. It is highly likely that they will 
die at a much younger age than their ancestors did in the past. The reasons for these changes 
are more complex. Genetic factors, lifestyle habits, medications, toxins, free radicals, body 
weight, psychological and social aspects, chronic stress, mental health, and social position 
play a significant role. 
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3. Late - onset hypogonadism and other diseases 
Testosterone levels in maturing man peak around age of 30 and then start to decline slowly. 
This decline in serum testosterone of aging men can lead to the development of many 
diseases (e.g. hypertension, ischemic heart disease etc.). The metabolic syndrome (defined as 
a combination of lipid abnormalities and cardiovascular risk factors), abdominal obesity, 
insulin resistance, arterial hypertension or raised blood pressure, are also associated with 
testosterone deficiency (Kalyani & Dobs, 2007). All men are at risk for erectile dysfunction 
and prostate diseases including Benign Prostatic Hyperplasia (BPH) and Prostate Cancer 
(PC), which occur in later years of life of men. Additionally, Alzheimer's disease and 
Parkinson's disease are both common in the elderly men, especially in those over 85. Low 
testosterone levels − a risk factor for development of visceral obesity − are associated with 
an acute decrease in circulating HDL cholesterol and increase of triglycerides. There may be 
a link between low testosterone levels in males and type 2 diabetes with elevated insulin 
levels. Some of these problems are due to the concentrations of total and free testosterone 
but there are also those that are associated with the derivatives of persistent testosterone 
deficiency. Late onset hypogonadism may result in the metabolic syndrome frequently 
leading to diabetes and/or to accelerated heart disease. When testosterone hormones in our 
body are balanced, the symptoms disappear. An increase in serum testosterone, results in 
normalization of lipid profile, improves glucose tolerance, decreases HbA1c, and produces 
the increase in bone mass observed in densitometry. Pharmacological correction of 
hormones results in marked improvements in the sexual health (increasing both libido and 
potency), removes  depression symptoms, and reduces or completely removes all symptoms 
of BPH and of Parkinson's disease. 
3.1 Late - onset hypogonadism is not just testosterone deficiency 
So far the aging process and clinical and biochemical changes which cause aging have been 
linked to reduction in testosterone concentration. This approach is, however, too simplistic. 
Testosterone is the direct precursor to estradiol, which is the most potent endogenous 
estrogen, and to many other hormone derivatives which have a significant impact on the 
normal structure and on the function of the human body. Therefore therapy to increase 
testosterone is inextricably linked with estradiol supplementation. Here special attention 
should be paid to the fact that not all preparations of testosterone can be converted to 
estradiol and to other derivatives, which makes such supplementation seem not to improve, 
but, sometimes, to make the situation worse. Estrogen affects the skeletal bone and 
cardiovascular systems in many radical ways. The decline in estrogen is associated with 
osteoporosis, premature atherosclerosis, marked risk of myocardial infarction, and with loss 
of bone mass (Gooren & Bunck, 2004).  
While testosterone can act directly on cells, it can also be converted to dihydroxytestosterone 
(DHT) by 5α-reductase. The same chemical reaction occurs which converts estradiol to 4-
hydroxyestradiol. In addition to hormonal effects, this compound has the peculiarity of 
saturation binding for dopamine receptors widely distributed in the brain. If one compares the 
chemical structure of dopamine with that of 4-hydroxyestradiol, it is possible to find the key to 
the dopamine receptor − a benzene ring with two hydroxyl groups attached to the ring − 
which can be seen in Figure 8. 
Dopamine receptors saturation in human brain has some very important implications of 
many physiological and pathological states. Dopamine deficiency causes Parkinson's 
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disease. Dopamine plays a crucial role in our mental health. Also, male sexual fitness is 
closely related to hormonal balance nd especially to dopamine and 4-hydroxyestradiol. 
Outlined below are some of the entities associated with testosterone deficit or with the 
deficit of testosterone derivatives. 
 
 
Dopamine             4-hydroxyestradiol 
Fig. 8. The dopamine structure and the 4-hydroxyestradiol structure. 
3.2 Late - onset hypogonadism and type 2 diabetes 
Clinical trial results have shown that men with type 2 diabetes have a significantly greater 
testosterone deficiency (Zitzmann & Nieschlag, 2006). In a large population study of subjects 
aged over 20, men with total testosterone levels in the lowest quartile and men with free 
testosterone in the lowest quartile had a 4-fold higher prevalence of diabetes compared with 
men with testosterone levels in the first quartile /p = 0.04/ (Muller et al., 2005). Metabolic 
syndrome, defined as a combination of lipid disorders and cardiovascular risk factors: 
abdominal obesity, insulin resistance, and arterial hypertension, also increases the risk for 
late onset hypogonadism ((Kalyani & Dobs, 2007). In my own research, out of 1200 men 
with late onset hypogonadism treated with hCG, more than 10 percent had diabetes. Raising 
the serum testosterone levels in these patients as a result of hCG therapy significantly 
improved glucose tolerance. Increasing testosterone levels, the average level of output being 
18.3 nmol/L-38.6 nmol/L, resulted in a reduction of HbA1c by an average of 1.75% 
(p<0.001). This effect is shown graphically in Figure 9. 
Normalization of HbA1c followed in the not-previously-treated diabetic group, as well as in 
the group of patients taking their medication without changing the dose. In some patients 
previously treated for diabetes, at the time of hCG administration, it was necessary to lower 
the dose or even to discontinue antidiabetic therapy. Among patients without known 
diabetes (HbA1c<6.0%), as a result of hCG therapy, HbA1c reductions were observed by an 
average of 0.5%. In patients with diabetes, insulin level was also determined. Average 
output level was 16.55 mU/L, and with intensified hCG therapy the average calculated 
insulin level was 7.8 mU/L.  
I believe that the term "insulin resistance" is overused. Insulin resistance does not cause 
diabetes. The inability to metabolize glucose (burn sugar), fully and continually is the cause 
of type 2 diabetes. An increase in the concentration of the glucose in the extracellular space 
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induces the increase in insulin levels. But insulin does not move sugar into cells when the 
cell-glucose level is equally high. Acceleration of tissue metabolism after injection of 
testosterone causes excessively fast burning of glucose, which decreases cell-glucose levels. 
Then, according to the concentration gradient, glucose enters the cell and this reduces 
extracellular cell concentrations of glucose. With the reduction of glucose concentration in 
the extracellular space, blood insulin levels fall below a certain level. Therefore "insulin 
resistance" does not apply in this case.  
 
 
 
 
Fig. 9. HbA1c normalization as a result of hCG therapy. 
3.3 Late - onset hypogonadism and hyperlipidemia 
As men age, there is a dramatic decrease in testosterone production, with a corresponding 
decrease in the production of estradiol. Excess lipids in the blood lead to atherosclerosis. 
Cholesterol, which can be very annoying, is in fact absolutely necessary. Too high or too low 
a concentration thereof has a detrimental effect. LDL cholesterol serves as precursor for the 
synthesis of steroid hormones. Moreover, every cell in the body requires LDL cholesterol to 
maintain cell wall integrity. With age, cell turnover is reduced. What is more, there are 
lower cholesterol production rates to create new cells. An excessive reduction of cholesterol 
levels in the body results in the deficit of raw materials for cellular renewal and in the deficit 
in the synthesis of steroid hormones. Various formulations are present in the treatment for 
hypercholesterolemia. However, hypercholesterolemia can also be normalized only by 
accelerating the metabolic processes. Anabolic testosterone boost effectively corrects the 
moderate lipid metabolic disorders. The hCG hormone therapy, which results in a 
significant increase in testosterone concentration and in E2 concentration (in testosterone 
level − from 18.3 nmol/L to 38.6 nmol/L; in E2 level − from 138.6 pmol/L to 280.9 pmol/L), 
improves lipid profile. There is a 15 to 20% decrease in total cholesterol and its fractions. 
This effect is shown graphically in Figure 10.  
www.intechopen.com
 Late - Onset Hypogonadism - New Point of View 131 
 
Fig. 10. Improved lipids during HCG-treatment hormonal treatment 
3.4 Late - onset hypogonadism and osteoporosis 
It is beyond discussion that women have osteoporosis as a direct result of ovarian hormone 
imbalance. In bone densitometry studies, 90% of those examined are females and only 10% 
are males; hence the great retardation of male endocrinology and of densitometric diagnosis 
of osteoporosis in men in relation to the same areas of medicine with regard to women. 
According to the recommendations of World Health Organisation, a woman should take 
hormone therapy early enough to avoid dangerous irreversible anatomical changes. What 
about a man? At puberty male estrogen can affect skeletal growth and bone mineralization. 
The study of men in the andropause also indicates a relation of estrogen level to bone 
mineral density (Riggs, et al. 2002). Studies have shown that two-thirds of the effects of 
testosterone replacement therapy (particularly with regard to increase in bone mineral) are 
due to excessive estrogen levels in aromatization of testosterone (Khosla, et al., 1998, Leder, 
et al., 2003). There is a clear relationship between the amount of androgens (bioavailable 
testosterone) and estrogens (bioavailable estradiol E2). In a large-scale study (data from 2623 
men over 65, enjoying good health) levels of free and bioavailable testosterone and 
bioavailable estradiol levels correlated. Low levels of bioavailable estradiol were associated 
with age and with osteoporosis (Orwoll, et al. 2006). In our own panel of 1200 patients, it 
was found that raising man’s testosterone levels to the values recommended for a given age 
was simultaneously accompanied by the increase of estradiol level. This caused the 
incorporation of calcium into bones, without any additional classical treatment of 
osteoporosis. The hormonal therapy used was to induce endogenous testosterone synthesis 
by human chorionic gonadotrophin (hCG). Please find below a depiction of the effects. A 
two year hCG therapy in a patient aged 60 years increased the bone density by 6.7% ( Figure 
11 and Figure 12); and a long-term therapy could help restore bone density to that of a fine 
young man. Figure 13 shows densitometric data of the chapter’s author (age 62y). Bone 
density of a fine young man − Young Ref (%) = 92.7; bone density with reference to age − 
Age Match (%) = 118.1 Z-Score = 1.26) 
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Fig. 11. 
 
 
Fig. 12. 
 
 
Fig. 13. 
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3.5 Late - onset hypogonadism, chronic prostatitis, BPH and prostate cancer 
It should come as no surprise to anyone that chronic prostatitis, benign prostatic hyperplasia 
(BPH), and prostate cancer (PC) are consequences of hormonal deficits. Prostate-specific 
antigen (PSA), a marker that has been used for many years in early prostate cancer 
detection, turned out to be less than 100% accurate to diagnose prostate malignancy. PSA 
was originally supposed to be a unique marker for prostate cancer. It was supposed to be 
just what its name implies – a specific marker. Over the past few decades an enormous 
amount of material has been written about the role of PSA in diagnosis of prostate cancer. 
Doctors started to use other PSA values - such as PSA velocity, PSA density, and percent-
free PSA - to get a more accurate idea of what was happening within the prostate. When the 
PSA reaches or exceeds the level of 0.5 ng/mL, it is strongly recommended to take all-out 
diagnostic measures, in order to ascertain the absence of PC (Gould, et al., 2006).  Practically 
in such cases, the biopsy of the prostate should be done. After a prostate biopsy, the PSA 
continues to rise, so the biopsy is repeated. This method often cannot give definite 
confirmation of prostate cancer, which has been the first dilemma. The other dilemma: what 
if the blood tests detect much lower levels of PSA? What if the reduction amounts to 2-3 
fold? Long-term clinical experience shows that a sudden significant increase in PSA level is 
possible with any surgery, after virus infection regardless of its location, or with regard to a 
severe exacerbation of chronic inflammatory diseases. A sudden increase in one’s PSA level 
should not escape the attention, but it is not equivalent to the occurrence or the 
development of prostate cancer. Changes in the PSA levels may be the consequence of the 
high levels of prostaglandins, which induce non-specific inflammations of the prostate 
usually seen in urine samples under a microscope. 
Harbitz stated over 30 years ago that male gonadal dysfunction (endocrine testicular failure) 
leads to adenomas and to the prostate cancer (Harbitz  & Haugen, 1974). It is an undeniable 
fact that testosterone levels peak in a man at approximately age 30, but this does not yet 
cause BPH or prostate cancer. And the older the man, and the greater the chances of 
testosterone deficiency, the higher the prevalence of benign prostatic hyperplasia and of PC. 
It can no longer be doubted, questioned, whether BPH and PC are closely related to the 
hormonal changes in men, and practically to testosterone deficiency.  
There are publications, which say that there was never any association between 
testosterone treatment, when subjects were all healthy men, and the increase of prostate 
volume and serum PSA level. They also say that in the treatment of men with 
hypogonadism, the therapy led to moderate prostate enlargement and to a 15% increase 
in PSA (Algarte-Genin, et al., 2004,  Behre, et al., 1994, Gould & Kirby, 2006). Among my 
own 1200 patients under treatment for hypogonadism, more than two-fold increase in 
endogenous testosterone concentrations after 37 months of hCG therapy resulted in a 40% 
decrease in their PSA levels. The aforementioned decrease is closely related not only to 
concentration of testosterone, but to the level of estradiol, which stimulates LHRH mRNA 
synthesis and increases pituitary LH synthesis. Testosterone deficiency does not cause 
prostate pathology. However, the losses of testosterone and long-term E2 deficiency result 
in the situation in which the hypothalamus and pituitary gland can become prostate's 
greatest enemies. Therefore, modern hormonal medications used to treat BPH have self-
stimulation points in the lateral hypothalamus (Oesterling, 1991, Reissmann, et al., 2000, 
Debruyne, et al., 2008).  
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3.5.1 Late - onset hypogonadism, BPH and chronic prostatitis 
The symptoms of BPH are practically only recognized when there are irreversible 
anatomical changes in the prostate, causing LUTS. Patients with BPH often see the doctor 
when they already have symptoms of LUTS. Meanwhile, the symptoms of chronic 
prostatitis will be in place long before that. Antibiotic or other medications are rather 
ineffective in those patients and the hormone therapy can help to relieve clinical symptoms. 
The effects of hormonal disbalance, including testosterone deficiency, can be seen on 
transabdominal and transrectal ultrasound scans. 
If hypoechoic areas in the transition zone of the prostate (marked with dots in Figures 
14÷17) are noted in ultrasound, it is a common sign of deficient testosterone levels. Such 
changes are occasionally described as inflammation and are not paid due attention to.  
 
  
   Fig.14.    Fig. 15. 
  
   Fig. 16.    Fig. 17. 
Figure 14.÷17. Ultrasound scan images of the prostate of testosterone deficiency patients. 
Figure 14 & 15. Transrectal ultrasonography. Figure 16 & 17. Abdominal examination. 
Hypoechoic area marked by dots. 
In my 30 years of being an urologist, I have treated hundreds of men diagnosed with 
prostatitis by other physicians. Antibiotics treatment could last several weeks or even 
months. Worst of all, it was not effective. Treatment with hCG led to the freedom from 
symptoms within 1-3 weeks. These symptoms were associated with the spread of prostate 
adenoma which, as it can lift the bladder, causes prostate inflammation symptoms. During 
hCG therapy, there is a reduction in adenoma, as demonstrated by MRI (Figures 18÷20).  
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 Fig. 18.     Fig. 19.   Fig. 20. 
Fig. 18. − 20. Prostate MRI before hCG therapy (Fig. 18), after 3 months of hCG therapy (Fig. 
19), and after 6 months of hCG therapy (Fig. 20). Arrows indicate regions of prostate 
adenoma − hyperplasia of the transition zone − which as a result of hCG treatment was 
markedly reduced. 
Some experts now recommend alpha-blockers and hormones as first-line treatment for 
patients with moderate to severe BPH symptoms. It must be emphatically stated that alpha-
blockers therapy appears to have no effect on the disease; it does not hinder its 
development; it only mitigates symptoms of BPH and facilitates urination. But after using 
alpha-blockers for a number of years adenoma can enlarge to the extent that surgical 
treatment becomes necessary. At the same time, there will be irreversible pathological 
changes of the bladder wall, which disrupt the normal function thereof. Thus, alpha-
blockers do not solve the problem of treatment for BPH. 
In hormonal therapy of BPH the agents used are: 1.- 5α-reductase inhibitors, and 2. - drugs, 
which inhibit LH synthesis or LHRH synthesis. 
Ad. 1. 5-alpha reductase inhibitors block the conversion of testosterone to 
dihydroxytestosterone. Their effectiveness in the management of BPH is debatable. Laurie 
Barclay, MD (Pfizer), issued a statement used in Pfizer commercial that Finasteride was no 
better than placebo in treating BPH symptoms. In fact, 5 alpha reductase inhibitors may 
cause hot flashes, decreased libido and impotence (Oesterling, 1991).  
In my opinion, this drug works, but its metabolic and functional consequences mean that 
the balance of potential profit versus loss can be harmful for men. Therefore I have not been 
using 5 alpha reductase inhibitors in the treatment of BPH. 
Ad. 2. In the treatment of BPH, other drugs have been used as well to decrease LH synthesis 
for more than 20 years. This effect has been achieved by LHRH analogues or LHRH agonists 
(Oesterling, 1991, Reissmann, et al., 2000, Debruyne, et al., 2008). This therapy, however, has 
significant disadvantages. It blocks testosterone endosynthesis, which leads to metabolic 
and functional complications. A fundamental question arises: What kind of man will 
deprive himself of potency and disrupt his normal body chemistry and metabolism in order 
to improve the health of his prostate? And so, shall we provide such a treatment, if it can 
block LH synthesis, and, while at the same time, more than a twofold increase in 
testosterone undoubtedly can positively affect the biology of man? 
3.5.2 LOH and prostate cancer 
Half a century ago arose the bizarre notion that testosterone was really dangerous and that 
it could cause prostate cancer. Years later, it became clear that there was no credible 
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scientific basis for the claim that high levels of testosterone accelerated development of 
prostate cancer. In fact, the opposite is true (Bonczyk, et al., 2008). The theory that 
testosterone may stimulate the growth of prostate cancer originates from 1941 when 
Huggins and Hodges reported that carcinoma was androgen-dependent. They 
demonstrated the importance of lowering testosterone levels in prostate cancer progression. 
Huggins and Hodges won the 1966 Nobel Peace Prize for their groundbreaking work 
revealing that castration causes regression of prostate cancer; while testosterone may cause 
its progression (Huggins & Hodges, 1941). It is now known that a multiplicity of data 
contradict Huggins and Hodges's contention that testosterone accelerates prostate cancer 
growth. Apparently it was negligent misinterpretation of one patient observation 
(Morgentaler, 2006). And they won the Nobel Prize. This caused a distorted look at the 
testosterone-prostate cancer link over the last half century. Even 15 years ago in Poland, 
testosterone was considered a carcinogen by Polish Ministry of Health and Social Welfare 
(Official Law Daily, 1996). There is no evidence that among men with prostate cancer, serum 
testosterone concentration is higher than in the rest of the population. On the other hand, 
low testosterone values coexisting with prostate cancer are associated with worse prognosis, 
a lower degree of differentiation, and a higher degree of severity of cancer (Morgentaler, 
2006, Yano, et al., 2007). Moreover, there is no convincing evidence showing the effect of 
testosterone on the development of pre-cancerous prostate condition. Rhoden et al. 
determined that the risk of the development of prostate cancer in hypogonadal patients 
receiving testosterone, with and without accompanying HG-PIN, does not increase with 
hormone therapy. After twelve months, the risk was 1,2% in men without HG-PIN, and 5% 
in men with HGPIN detected. The aforementioned values do not exceed those in the general 
population (Rhoden & Morgentaler, 2003). At the same time, one can find statements that 
there are two classic contraindications for the administration of testosterone, namely 
suspected or histologically proven prostate cancer and symptomatic benign prostatic 
hyperplasia (Montorsi, 2007). While I understand precautions that most men with prostate 
cancer should avoid testosterone therapy, even though I use it for my patients, a total ban on 
the use of testosterone to treat BPH appears to be an anachronism.  
25 years ago, Fowler and Whitmore proposed the concept of “saturation” in order to explain 
the relationship between prostate cancer and serum testosterone levels. It explains why the 
increase in serum testosterone levels in patients treated with that hormone does not cause 
the disease (Fowler & Whitmore, 1981). The correctness of this concept is confirmed by 
observations of patients, despite treatment with T, there was no increase in PSA or prostate 
volume. In men suffering from hypogonadism the treatment did not lead to excessive 
growth in prostate size, and it led to an only 15% increase in PSA (Algarte-Genin, et al., 
2004, Gould & Kirby, 2006). Currently, it is believed that exogenous testosterone treatment 
in patients with PC, which does not follow androgen ablation, should not worsen 
prognosis of cancer (Bonczyk, et al., 2008). It has long been feared that the Late Onset 
Hypogonadism (LOH) treatment by administering testosterone may increase 
the risk of high-grade prostate cancer. Numerous studies show that there is no PSA increase 
during testosterone therapy. Among my own 1200 patients under treatment for 
hypogonadism, more than two-fold increase in endogenous testosterone concentrations 
after 37 months of hCG therapy resulted in a 40% decrease in their PSA levels. In each age 
group − and the older the man, the more severe it is − there are patients who present 
insufficient endosynthesis, but they constitute only a few percent of total number of 
patients. During the extended follow-up of these patients, it has been found that 14% of 
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them have had some form of prostate cancer within 3 to 36 months. The results clearly show 
that there is a greater decrease in endogenous testosterone synthesis, but at the same time 
there is an increased risk of prostate cancer. The patients in question had very high LH/PSA 
ratio. Therefore prostate cancer is not caused by testosterone, but, to the contrary, it is a 
consequence of the development of testosterone deficiency. Moreover, there is a correlation 
between testosterone levels and the degree of PC malignancy (Hoffman, et al., 2000). It has 
been known for years that patients diagnosed with prostate cancer and with high Gleason 
scores, have lower than normal levels of testosterone. Lower testosterone levels result in 
greater PC malignancy (Schatzl, et al., 2001). Patients with high Gleason score prostate 
cancer have lower testosterone and estradiol serum levels. 
There is also no evidence that men with prostate cancer have a much higher testosterone 
concentration than the normal population. On the other hand, low testosterone values found 
in men with prostate cancer are associated with poorer prognosis, with a lower degree of 
differentiation of PC, and with a higher degree of PC severity (Hoffman, et al., 2000, 
Morgentaler, 2006, Yano, et al., 2007). In men treated with testosterone, prostate cancer was 
detected in biopsies of 1% of patients, while in men with the prevalence of hypogonadism − 
in 14.3%. There are some reports that testosterone therapy may reduce the risk of prostate 
cancer (Fowler & Whitmore, 1981, Prout & Brewer, 1967). Only some reports, because who 
would dare to publish anything incompatible with the study by Nobel laureates? 
3.6 Late - onset hypogonadism, sexual drive, potency and libido 
For many years, we have been reassured that only androgens have a key role in both 
stimulating and maintaining sexual function in men. It was believed that testosterone and 
the existence of a normal level of libido were inseparably connected (Shabsigh, 2003, 
Morales, et al., 2004). Nevertheless, sexual dysfunction in men is directly associated not only 
with testosterone but also with estradiol (E-2) and with other neurohormonal factors. 
Erectile dysfunction was linked to the development of benign prostatic hyperplasia (BPH), 
without even taking into account the fact that both benign prostatic hyperplasia (BPH) and 
erectile dysfunction (ED) were often caused by the hormone deficit. The effects of women's 
hormone replacement therapy on their psychological and sexual functioning are still the 
subject of the research in the borderline field between medicine and psychology. Female 
hormone therapy in treating menopause is common around the world. Meanwhile, several 
years ago it was stated that the effects of this therapy on men were not known. Hormone 
replacement therapy for men has been lagging for at least 20 years compared with hormone 
replacement therapy in women (Tenover, 1999). There is a decline in testosterone 
production in elderly men that can lead to a decrease in sexual desire  (Kaufman & T’Sjoen, 
2002). Androgen therapy can stop and even reverse this degenerating process (Hajjar, et al., 
1997, Morales, et al., 2004). Information on the importance of testosterone in male sexuality 
is often divergent. It is known that surgical and pharmacological castration leads to 
impotence. On the other hand, it is recognized that testosterone deficiency is considered to 
be of little importance in the development of erectile dysfunction or in life force. (Anderson, 
2003, Montorsi et al., 2003).  
There was no sexual orientation change in men who underwent surgical castration. Sexual 
desire was preserved by the majority of the patients, but interest in sex decreased, which 
was associated with decreased frequency/intensity of orgasms (Zverina, et al., 1990). 
Testosterone replacement therapy suitable for men with primary testicular failure as a result 
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of surgery conduces to a return to good sexual health and to good psycho-social outcomes 
(Fossa, et al., 1999). A drop in men’s testosterone levels results in reduced libido and sexual 
potency. The implementation of hormonal therapy in hipogonadal men at the time when 
testosterone levels increase significantly, approaching the upper limit for normal, causes 
regular nocturnal erections. It also increases the number of spontaneous erections and it 
increases sexual activity (Burries, et al., 1992, Tariq, 2002). Other authors also propose that 
libido is closely tied to testosterone levels and that hormone replacement therapy increases 
the frequency of sexual thoughts and significantly improves one's libido (Davidson, et al., 
1982, Kwan, et al., 1983). Testosterone induces nitric oxide synthesis in vascular 
endothelium through its influence on arginase activity. This leads to the opening of vascular 
pathways; facilitates blood flow into the corpora cavernosa; and enhances penile erection. 
The same mechanism is used in treatment of erectile dysfunction (ED) with PDE-5 
inhibitors. It is currently the primary means of treating ED. 
However, such treatment might not be effective when there is a decrease in male libido (the 
decrease being one of the symptoms of andropause) as a result of a decrease in the level of 
testosterone which is a hormone produced in a man's testicles. The occurrence of erectile 
dysfunction causes an increase in depression. Meanwhile, the treatment of depression 
through the introduction of SSRIs (selective serotonin reuptake inhibitors) affects the 
deterioration of erectile function in a secondary way (Hsu & Shen, 1995, Keller, et al., 1997). 
Thus, Andropause Erectile Dysfunction Treatment and male depression treatment are often 
ineffective. It is worth remembering, however, that andropause can start from any age but 
generally around age 30, a relatively young age, when a man still has some 40 years of life. 
Erectile dysfunction, especially in young men, has not yet been linked with their hormonal 
status. 
I have found that during hormone therapy my patients are affected by changes in their 
sexual health. A thorough analysis of the problem became the subject of the doctoral 
dissertation of one of my assistants (Czyżowska, 2009). 
My research on 88 men aged 20-68 years, (mean age 45), clearly shows an increase in 
testosterone endosynthesis at the time of hCG Hormone Therapy, on average from 17.93 
nmil/L to 40.86 nmol/L. At the same time, a significant increase in E-2 was found in those 
examined, on average from 168.72 pmol/L to the value of 332.44 pmol/L. The change in 
hormone levels of those examined resulted in a significant improvement in their sexual 
performance, in libido and in erectile potency, evaluated using the International Index of 
Erectile Function (IIEF-5) questionnaire. The average value of IIEF-5 before therapy was 13.4 
points (SD = 5.0), and during therapy − 19.88 points (SD = 4.3). The data are shown in 
numbers in Table 7, and graphically in Figures 21÷22. 
 
 
Before therapy 
(average, SD) 
During therapy 
(average, SD) 
Significance 
Testosterone 17.937 nmol/L, 7.11 40.89 nmol/L, 12.55 p<0.0001 
Estradiol 168.72 pmol/L, 77.9 332.44 pmol/L, 141.72 p<0.0001 
IIEF-5 13.4, 5.0 19.876, 4.3 p<0.001 
Table 7. Average hormone concentrations and the IIEF-5 score before and during treatment 
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Fig. 21. Average IIEF-5 score before treatment 
 
 
 
Fig. 22. Average IIEF-5 score during treatment 
According to the Arizona Sexual Experiences Scale (ASEX), there was also a significant 
improvement in sexual health, from an average of 17.39 points (SD=4.24) before treatment to 
12.45 points (SD=3.57). The average ASEX values distribution has been shown in Table 8. 
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Before therapy 
(average, SD) 
During therapy 
(average, SD) 
Testosterone 17.937 nmol/L, 7.11 40.89 nmol/L, 12.55 
Estradiol 168.72 pmol/L, 77.9 332.44 pmol/L, 141.72 
Scale – ASEX 3.9 3.4 3.6 3.1 3.3 2.6 2.3 2.6 2.5 2.5 
Table 8. Average hormone concentrations and the Arizona Sexual Experiences Scale 
measurement before and during therapy. 
As noted above, serum concentration of E-2 plays a dominant role in male sexual health. 
Low levels of aromatase, which result in extremely low E-2 concentrations, may, 
nevertheless, be important in male sexual performance without affecting sexual orientation 
and gender identity (Gomuła, 2006,  Gomuła, 2007). In patients with congenital absence of 
aromatase only the low-dose E-2 substitution results in significant changes in sexual 
behavior. Estradiol administration leads to increased erotic fantasies, masturbation or sexual 
activity Carani, et al., 1999).  
My own research clearly shows that E-2 is required to maintain sexual functions in adult men 
(Gomuła, 2007). The manifestations thereof have been observed after prolonged hormonal 
therapy. Androgen deficiency patients had their testosterone levels increased for therapeutic 
purposes. During the therapy, a parallel increase occurred in serum E-2 concentrations, as the 
effect of the all natural aromatase. Some patients had such high E-2 levels that they exceeded 
the normal physiological range. In order to reduce E-2 concentration, my patients received 
preparations blocking aromatase activity. As a result of this therapy, men characterized by 
high concentrations of testosterone (falling in the upper limits of normal), whose E-2 was 
detected at very low levels, had a total loss of libido. At the same time those men suffered from 
erectile dysfunction, which could even lead to inability to initiate or maintain an erection. 
Stopping the drug which blocked aromatase resolved the symptoms and resulted in a rapid 
return of high concentrations of E-2. Some authors report that in the activation of male sexual 
behavior the brain level conversion of testosterone to estradiol is of major importance and that 
testosterone's effects are not in themselves so important (Balthazar & Ball, 1998). Testosterone 
has a significant effect on the smooth muscle in the corpora cavernosa. Androgens may 
significantly affect the ultrastructure of the corpora cavernosa and these changes are 
responsible for erectile dysfunction (Traish & Kim, 2005). 
In young men, the ratio between smooth muscle and stroma in the corpus cavernosum is 
1:1. Long-term hypogonadism causes the ratio of contents in muscle tissue to be 1:5, which 
results in smooth muscle atrophy and in fibrotic changes of the corpora cavernosa (Yassin & 
Treish, 2004).  
Fig. 23 represents normal cavernosal histological appearance and its loss as a result of 
testosterone deficiency, according to Yassin (Yassin & Treish, 2004).  
Androgen replacement can lead especially in hypogonadism patients to recovery process 
within the trabecular tissue. This result means that testosterone therapy supports the 
“recovery process” not only in striated muscles in human body /reversible process/ (Yassin 
& Treish, 2004).  
The basic question arises as to what should the first step be in a successful erectile 
dysfunction prevention and in a successful erectile dysfunction treatment? If the decrease in 
testosterone leads to penile tissue fibrosis, smooth muscle atrophy in corpora cavernosa, and 
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damage to mechanisms blocking the blood flow from the corpora cavernosa, how do PDE-5 
inhibitors pour the proverbial oil on the troubled waters? And at the same time testosterone 
restores penile smooth muscle.  
 
 
Fig. 23. Aging changes in the cavernosal tissue (Fig. 23-V) can also be induced by androgen 
deprivation (Fig. 23-E). The ratio of smooth muscle compartment to connective tissue which 
is normally 1:1 (Fig. 23 C & T) would suffer a shifting till 1:5 (Fig. 23 V & E) with a higher 
mRNA concentration as an expression of increasing number of alpha adrenoceptors 
according to Yassin (Yassin & Treish, 2004).  
Testosterone deficiency is closely linked to the reduction in libido. And when one's libido is 
lowered, the effectiveness of PDE-5 inhibitors is also limited. In such situations, the 
preventive and curative procedure is to maintain adequate testosterone level in the body. 
What is more, in patients receiving PDE-5 inhibitors, the increase in the concentrations of 
testosterone can improve the penile vascular blood flow, which is yet another argument for 
using the aforementioned procedure. 
It is also known that diabetes can increase the problem of erectile dysfunction. It was 
previously believed that diabetes lead to lower testosterone levels. In contrast, quite the 
opposite is happening. A drop in testosterone levels due to a decrease in glucose uptake 
facilitated by anabolism reduction causes diabetes. Increased levels of testosterone 
significantly improve glucose tolerance and reduce one's insulin levels and the HbA1c 
level. Testosterone deficit can thus affect sexuality, both at a particular moment and 
through changes in metabolic processes leading to vascular lesions. There may also be a 
significant delay in the increase/drop in testosterone, even for many years, which may 
lead to erectile dysfunction (Gomuła, 2006). Some argue that the very fact of the 
occurrence of erectile dysfunction, rather than the testosterone concentration level, is the 
main indication for hormone replacement (Shabsigh, 2003). But the mechanism of erection 
is based not only on testosterone levels. It is not based merely on the E-2 either. Because 
neither testosterone nor E-2 alone determine the adequacy of an erection. If the 
mechanisms of erection depended on changes in serum testosterone levels, one would 
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have to wait many hours for an erection. Testosterone concentrations and E2 
concentration  increase as a result of natural endosyntesis. This lasts about 6 hours 
because that much time elapses from the original signals for spectral contrast in visual 
cortex during the first stage of sleep, rapid eye movement (REM). And the highest 
concentration of testosterone for a man is at approx. 4-5 am, after about six hours of sleep. 
The mechanisms of erection depend on such factors as the concentration of hormones, but 
they do not depend on them in a direct way. To obtain or maintain an adequate erection, 
one needs adequate levels of testosterone and of E-2. Therefore, aromatase, which 
converts testosterone to E-2, is also essential. Arginase, which induces the synthesis of 
nitric oxide in vascular endothelial cells,  also plays an important role. 4-hydroxyestradiol 
derivative of estradiol is a substance that at the level of brain activity plays perhaps the 
most important role therein. 4-hydroxyestradiol has this property that it may saturate 
dopamine  receptors in the brain. At high saturation level, dopamine stimulates these 
receptors, causing penile erection. Release of dopamine, which is one of many 
neurotransmitters, occurs rapidly. These two mechanisms are shown in Figure 24. 
 
 
 
 
Fig. 24. Erection occurs as a result of the involvement of neurotransmiters, secreted at the time 
counted in seconds, and does not depend on hormonal changes, which can last for hours. 
It clearly shows that we need to revise our views on the impact of hormones on our 
sexuality, potency, and libido, because not just hormones but also brain neurotransmitters 
have an impact on male sexuality.  
3.7 Late - onset hypogonadism and depression 
I have observed in my patients a change in their mental condition while they were under 
hormone therapy. A state of depression transformed itself into a state of joy. This gave 
www.intechopen.com
 Late - Onset Hypogonadism - New Point of View 143 
enough reason to conduct a thorough analysis of the problem, which turned out to be the 
topic of the PhD dissertation of one of my assistants (Czyżowska, 2009). 
Depression is a serious medical condition where a person may feel “down” or “hopeless” 
for weeks or more. According to the National Institute of Mental Health, the signs and 
symptoms of depression include: persistent sad, anxious, or “empty” mood; feelings of 
hopelessness, pessimism; feelings of guilt, worthlessness, helplessness; loss of interest or 
pleasure in hobbies and activities that were once enjoyed, including sex; decreased energy, 
fatigue, being “slowed down”; difficulty concentrating, remembering, making decisions; 
insomnia, early-morning awakening, or oversleeping; appetite and/or weight loss, or 
overeating and weight gain; thoughts of death or suicide, suicide attempts; restlessness, 
irritability; persistent physical symptoms that do not respond to treatment, such as 
headaches, digestive disorders, and chronic pain. Treatment of sexual disorders caused by 
depression with antidepressants based on Selective Serotonin Reuptake Inhibitor (SSRI) has 
a secondary detrimental effect on erection (Hsu & Shen, 1995, Keller, et al., 1997). It results 
in a vicious circle – antidepressants increase erection disorders, while sexual life disorders 
intensify depression. The circle is closed. How can it be broken? 
Evidence proving therapeutical effect of estradiol in depression disorders has been found 
amongst women, however the research has not proven explicit relation between the 
estradiol level and depression among men (Studd & Panay, 2004). Neurosteroids produced 
in the central nervous system from cholesterol or other steroidal precursors are responsible 
for direct functioning within the brain, while alterations in their production typical for 
menopause in women and men cause certain aging symptoms. They directly influence, for 
example, body temperature regulation (hence the heat waves and cold sweats symptoms), 
memory function and emotions. Situational factors experienced by the given person, such as 
stress, secondarily disturb their secretions of hormones (Carruthers, 2004).  
Research results demonstrated that hormone therapy for men, with hCG inducing testosterone 
endosynthesis causing over a double increase of testosterone and E-2 concentrations, result in 
substantial improvement of psychological condition and not only relieve depressive states, but 
also causes a progression from depression to the state of joy of life.  
Based on the author’s own research on 88 men aged between 20 and 68 years, (mean age 45 
years), during the hormone therapy with hCG testosterone endosynthesis increase was 
achieved from E-2 average value 168.72 pmol/L up to 332.44 pmol/L. The change of 
hormonal state of the subjects resulted in substantial improvement of their psychological 
state assessed on the basis of extended Beck Depression Inventory /BDI/ (Beck, 1967).  
The classic BDI evaluates exclusively depressive state. Condition above zero is not 
assessed, only depression is included. Accepting BDI as a good test however not designed 
to evaluate joy of life state, I have developed the questionnaire adding reflection towards 
opposite direction, i.e. towards joy of life. Implementing such a tool for analysis of 
patients’ psychological state enabled the change of hormonal condition to be 
demonstrated as not only what causes relief from depression, but also progress to the 
state of joy of life.  
Restoring man’s normal concentration of testosterone and E-2 results in significant 
improvement of his mental health; depressive states subside. Furthermore, patients who 
prior to treatments were below state “0”, in depression, during the therapy note states 
significantly above state “0”; they move to the joy of life state, as presented in Fig. 25.  
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Fig. 25. Psychological state according to BDI: before the therapy – red, after the therapy – 
green. Patients who suffered from depression are in the joy of life area during the treatment.  
The facts above presented explicitly demonstrate a close correlation between hormonal and 
psychological states of man.  
3.8 Late - onset hypogonadism and Parkinson's disease 
Although Parkinson’s disease (PD) is diagnosed in only 0.1% of the total population, in the 
population older than 70 years of age its prevalence reaches 1%. The mean age of 
developing the disease is 58 years, and PD affects men more frequently than women /1.6:1/ 
(Edwards, et al., 2002, Nelson, 2002). The main cause of PD is the degeneration of 
dopaminergic neurons of substantia nigra in the nigro-striatal system of the brain. The 
development of the disease is believed to be triggered by both genetic and environmental 
factors. So far there have been very few reports in the literature, linking PD with the 
hormonal condition of a patient. Yet numerous symptoms resulting from the deficiency of 
such sex hormones as testosterone in men and progesterone-estrogen group in women, may 
co-exist with motor and other PD symptoms. These include impotence, lowered joy of life, 
lack of energy and mental depression (Edwards, et al., 2002, Nelson, 2002). Experimental 
studies have shown that estrogens can protect hippocampus neurons against beta-amyloid 
protein, which is implicated in the development of PD. The estrogens influence a creation of 
new synapses and improve the survival of neurons in hippocampus region (Serwin, 1994, 
Okun, et al., 2001).  
Recent studies suggest the existence of morphogenic influence of estrogens on neurons and 
on plasticity of synapses. Estrogens appear to provoke synapsogenesis in hypothalamic 
cells. Apart from that, nonspecific systems activating brain neuroplasticity processes seem to 
be modulated as well (Skibińska & Kossuth, 2003).  
The neuroprotective action of estradiol is connected with oxidation processes. Oxidative 
stress is known to be important in the process of dopaminergic neuronal degeneration in 
Parkinson’s disease, whereas estrogens have neuroprotective effects in neurodegenerative 
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disorders (Sawada, et al., 1998). HRT in men has been used only recently and never so 
widely as in women, thus we have less experience for HRT in men. 
Regardless of the fact that the relation between dopamine and androgens at the level of the 
central nervous system is still not absolutely clear, on the basis of my own clinical 
observations it can be stated categorically that in men there exists a strong correlation 
between the hormonal system and PD symptoms. This statement is supported by the initial 
examinations and observation of PD patients who consider to undergo HRT. 
The preliminary study comprised of 16 men suffering from PD and LOH, aged 64 –78 years. 
The hCG therapy used was to induce testosterone endosynthesis. The follow-up lasted from 
1 to 4 years. 
Following the therapy, the serum testosterone concentration increased from the mean 
baseline level of 12.3 nmol/l to 34.8 nmol/L. So far, the main parameter that has been 
considered for HRT in men has been the testosterone concentration. When the hCG was 
administered, though, the testosterone concentration increase was accompanied by 
simultaneous increase of estradiol level. In the analysed group of patients, the increase of 
the mean estradiol level was from the baseline of 46 pmol/L to 189 pmol/L. 
The addition of the hormonal therapy was supplemental to the standard long-term 
pharmacological anti-PD treatment. As a result of this addition, a dramatic improvement of 
PD symptoms was observed.  
Before the hormonal therapy began, the patients complained of motor latency and 
insufficiency, hand tremors, muscular tremor and rigidity in legs. During the treatment 
these symptoms clearly improved or completely disappeared. 
Just stating the fact, though, without being able to document it, may justly be questionable. 
Numerical assessment and analysis of parameters from various questionnaires are 
ambiguous. That is why every possible effort has been made to present undeniable proof 
and evidence of beneficial changes in the clinical condition of PD patients. The first evidence 
for the relationship between LOH and clinical symptoms of PD is the film which was  
shown during ISSAM Seminar ‘Androgen Deficiency in the Adult Male’ at the 4th World 
Congress of The Aging Male in Prague. 
Dr Malcolm Carruthers, a Congress participant, wrote in his book, published a few months 
after the Congress:“The results showed that after treatment, Parkinsonian symptoms greatly 
improved. Physical symptoms of slow, limited movement (bradykinesia), hand tremor, 
muscular tremor and rigidity of the legs clearly improved or disappeared, as did standing 
and walking alone, and ease of movement. Daily activities of living such as eating, dressing, 
personal hygiene and handwriting were all made easier. Clear improvements in many 
symptom areas were also documented by the film evidence” (Carruthers, 2004). An excerpt 
of the film can be seen on www.medan.pl. 
The mental condition of the patients also improved substantially. The patients who had 
been slow, even dull, depressive, unwilling to contact with others, once the therapy 
commenced, changed dramatically. 
After the hCG therapy was introduced, PD and other accompanying symptoms improved 
noticeably. Dyskinesis and involuntary body functions, being the adverse effects of 
treatment with L-dopa, discontinued or occurred sporadically.  
If any patients had not been able to stand up, that problem disappeared. Now the patients 
could walk by themselves. They also reported that the way they moved had improved. 
Without any help of others, they could walk on an uneven ground or even stroll in woods. 
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The patients were able to eat their meals without any help, they could normally use a spoon, 
a knife and a fork because the hand tremor stopped. They could do their shirt and coat 
buttons up, and needed no help from others to get dressed or to wash themselves. 
Another important objective element of improvement was the disappearance of sialosis. 
Their handwriting also improved, became clearer, with no traces of tremor or 
micrographism. 
In 5 out of 16 patients described here, the improvement of their quality of life (QOL) also 
included the sexual function. Both their libido and potency improved. They resumed sexual 
activity, in which they had been inactive for a long time. 
The hormonal therapy enabled them to live as before they fell ill, without having to be 
helped by others. Their quality of life benefited from that situation too. Their caregiving 
families felt extremely relieved. PD patients’ families voluntarily admitted that the 
hormonal therapy was effective not only for PD sufferers but it improved quality of life of 
their families as well. 
Initially, the PD-treatment regime had been kept. Neither the drugs nor their doses had been 
changed. After a few months of hCG administration, though, it was possible to lower the 
dosage or even withdraw certain anti-parkinsonism drugs, without aggravation of PD 
symptoms.  
In the study presented, there was no control group. Yet, when the hormone-stimulation 
therapy was stopped, the patients’ condition and symptoms clearly deteriorated, returning 
to what they had been like before the hormonal treatment was administered. Once the 
hormonal therapy was restarted, parkinsonian symptoms disappeared again. That fact was 
observed by patients and by their families as well. 
Parkinson’s disease and hormonal deficiency are inextricably linked. Both men and women 
suffer from Parkinson's disease because of deficit of estradiol, and more specifically because of 
the deficit of 4-hydroxyestradiol (dihydroxyestradiol), which is a derivative of estradiol. The 
molecular structure drawings, which illustrate how dopamine and 4-hydroxyestradiol are 
attached to the same key site to dopamine receptor in the brain, as given above, are in the 
subsection 2.1. Late Onset Hypogonadism is not just testosterone deficiency. And it is only 4-
hydroxyestradiol - a chemical compound, which due to its chemical structure, may saturate 
dopamine E-2 receptors in the brain. Therefore, in the treatment of Parkinson's disease special 
attention should be paid not only to testosterone levels, but particularly to the concentration of 
E-2. The desirable concentration of E-2 is approximately 250-300 pmol/l. This implies, 
however, maintaining also excessively high levels of testosterone, which cause hyperactivity in 
patients. In such cases, apart from hCG injections, I resort to microdoses of transdermal E-2 
treatment in order to obtain the desired physiological serum levels of testosterone.  
3.9 LOH and mortality & morbidity from coronary artery disease  
Cardiovascular diseases, which include CAD, are now the biggest killer in the developed 
countries. The mortality rate from CAD varies by a factor of five in different populations in 
the world. Yet, in spite of such a high range in mortality rate, the ratio of male-to female  
deaths is relatively constant at more than three-to-one (Tunstall-Pedoe, 1999). This cannot be 
explained solely by differences in the risk factors for cardiovascular disease, between the 
sexes (Rayner, et al., 1998). The remarkably lower prevalence of CAD is particularily 
prominent in pre-menopausal women, but increases slightly after the menopause (Kalin, & 
Zurnoff 1990).  
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These facts led to the notion that diminshing levels of testosterone in aging men, which lead to 
late onset hypogonadism (LOH), are responsible for such differences and higher mortality of 
men. Indeed, the nested case-control study on 11’600 men aged 40 to 79 years (EPIC-Norfolk 
UK) showed inverse relationship of endogenous testosterone concentration and mortality due 
to cardiovascular disease and all causes including CAD and cancer. This study clearly 
suggested that high endogenous testosterone concentrations appear to lower mortality rates of 
men due to all causes, cardiovascular disease and cancer (Khaw, K.T., et al., 2007).  
In the “Hypogonadism in Males (HIM)” study (Mulligan, et al. 2006) on 2162 male patients 
over 45 years of age and visiting their primary care physicians for general reasons, it was 
found that 38.7% of them were hypogonadal and 3.7% of them were receiving testosterone. 
Among men not receiving testosterone, odds ratios for having hypogonadism were 
significantly higher in men with arterial hypertension (1.84), hyperlipidemia (1.47), diabetes 
(2.09), obesity (2.38). Conversely, late onset hypogonadism (LOH) and the Testosterone 
Deficiency (TD) connection with cardiovascular disease is evident from TD associations 
with diabetes (Dhindsa, et al. 2010) and metabolic syndrome (Kalyani & Dobs, 2000) and 
such findings as an inverse relationship between testosterone level and aortic 
atherosclerosis, which was seen among middle-aged and older men in the Rotterdam Study 
(Hak, et al., 2002). 
Low free testosterone has also been associated with abdominal aortic aneurysm in 
community-dwelling men aged 70-88 years (Yeap et al., 2010). Furthermore, for men aged 50 
to 91 years of age who were followed for 20 years in the Rancho Bernardo Study (Barrett-
Connor et al., 1999), serum testosterone levels were inversely related to weight, body mass 
index, arterial blood pressure, serum insulin and plasma glucose. Nevertheless, as these 
factors may be relevant to mortality there was clear evidence that men with serum 
testosterone concentration below 25th percentile had a 40% higher risk of death, 
independent of obesity, lifestyle choices (eg. exercise, smoking) and age (Laughlin, et al., 
2008, Tivestena et al., 2009). Another 5-year retrospect study on male veterans (N=858), 
compared mortality of men with normal (± 450 ng/dL) T levels to those with low (<250 
ng/dL) total testosterone  and low (< 0.75ng/dL) free testosterone levels (Shores, et al., 
2006). The results showed that mortality for subjects with low T was almost twice as high 
(34.9%) as for those with normal T levels was 20.1%. There is an obvious link between  
mortality and morbidity due to coronary CAD and other cardiovascular diseases and LOH 
due to low free testosterone levels in serum of aging men (Wu & von Eckardstein, 2003, Wu, 
et al., 2010). This is due to existing strong correlation of  testosterone defficiency with 
glucose tolerance, visceral obesity, serum lipid disorders and elevated arterial pressure 
(Kalyani & Dobs, 2007). These factors usually lead to vascular disorders. The clinical studies 
(English, et al., (1997) showed that low natural androgen concentration can cause 
deletorious changes in atherogenic lipid profile, high fibrinogen and a hypercoagulable 
state, an increase in insulin resistance and hyperinsulinemia, higher systolic and diastolic 
blood pressures. The biologically plausible mechanism of testosterone protective action 
against cardiovascular disorers can be explained by the fact that testosterone has direct 
vasoactive properties (English, et al., (1997). In animal models of isolated coronary, femoral 
and pulmonary arteries testosterone showed a dose-dependent vasodilatory effect (Channer 
& Jones, 2003). It is caused by a direct effect on the vascular smooth muscle, by either an 
effect on potassium or calcium channels (Deenadayalu, V.P., et al. 2001, English, K.M., 2002). 
In man, testosterone has been shown to cause dose-dependent vasodilation both in vitro and 
in vivo. During cardiac surgery on man, the coronary artery diameter and subsequent 
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coronary flow immediately increased when testosterone was injected via intracoronary 
indwelling catheter (Webb, C.M. et al., 1999). 
During the non-invasive therapy of LOH when the increased T concentration levels can be 
sustained for longer periods. T can not only protect man against atherogenic factors but also 
may cause long-term coronary dilatation. This is due to testosterone interaction with 
arginase activity, which results in increased synthesis of nitric oxide in endothelial cells in 
the entire vascular system. Nitric oxide is a well known vasodilator, which acts systemically. 
The synthesis of NO is also used in the treatment of erectile dysfunction (ED) by applying 
fosfodiesterase 5 inhibitors (PDE-5-I). Interestingly, nowadays these PDE-5 inhibitors 
become popular as a treatment of choice for some cardiovascular diseases.   
Large scale clinical studies on long term effects of treatment of LOH with hCG on CAD were 
not yet reported, but case reports from my colleagues in cardiology who clinically follow 
some of my patients with exercise tests, are positive, including diminshing or disappearance 
of so called angina pectoris pain.  
3.10 Late - onset hypogonadism and immune resistance   
I have no scientific evidence to support any representation of a change in the immunity in 
my patients undergoing hormone therapy. Conducting such research is practically very 
difficult, perhaps impossible. Antibiotics, aspirin, and anti-inflammatory drugs should not 
be taken for at least a year by patients who have their immune status tested. This is 
impossible!!! But I can say with conviction that men whose testosterone levels increased 2-
fold during hCG therapy as well as those already experiencing androversion (for 
androversion see 3.3 LOH and  androversion) claimed that they did not get colds and that 
they had no infections, which they had had quite often before. 
4. The treatment of late - onset hypogonadism 
Now, the most widely practiced therapy for men with LOH are injections of testosterone 
esters or transcutaneous applications of 1% and 2% testosterone gel preparations. This is 
because many years ago it was erroneously believed that, with age, all men lose their ability 
for endo-synthesis of testosterone.  
Another method known over the past 50 years, presently gaining "renaissance" of 
recognition, has been the stimulation of testosterone endo-synthesis by administering hCG 
(Gould, 1951, Gomula, 2001, Gomuła, 2002-a, Gomuła, 2002-b, Gomuła & Twarkowski, 2002, 
Gomuła, 2006, Gomuła, 2007). 
The serum testosterone concentrations observed in patients treated with hCG increased by 
at least 150% and up to 200% (Gould, 1951, Janczewski, et al., 1966, Gomuła, 2001, Gomuła, 
2002-a, Liu et al., 2002, Gomuła, 2007, Gomuła & Rabijewski, 2010). 
Yet, if applying hCG makes it possible to almost double testosterone concentration, why to 
inject testosterone esters to men when they still have the ability for endo-synthesis of their 
own, natural testosterone?    
The hCG therapy improves testicular function, while treatment with synthetic testosterone 
inhibits it. Years ago, there was a trend to produce oral contraceptives for men but this idea 
was soon abandoned. That oral contraceptive for men was supposed to be testosterone ester 
pill. The information that taking synthetic testosterone not only inhibits spermatogenesis, 
but also inhibits male’s own testosterone endo-synthesis, is now almost labeled as 
“classified”. In fact, after three months of taking synthetic testosterone, a man becomes 
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totally infertile (WHO, 1990,  Wallace, et al., 1993, Anderson & Wu, 1996, Zhang et al., 1999, 
Baird, 2002, Anderson & Waites, 2003, Si-Tian, et al., 2004). Furthermore, long-time 
testosterone therapy may result in irreversible testicular atrophy. From this moment on, a 
man becomes dependent on taking testosterone. The discontinuation of testosterone intake 
leads to metabolic disorders, which may cause many other diseases to develop. 
4.1 Late - onset hypogonadism and hCG therapy 
The effect of the treatment of 908 patients taking hCG was described in 2010 (Gomula & 
Rabijewski, 2010). Below, I present a further study of 1200 men (age range 20-89 years; 
mean, 54). Mean follow-up period of the patients was over 37 months.  
During the therapy with hCG (2 x 5000 i.u. per week) there was an average increase in 
serum concentrations of total testosterone from 18.4 nmol/L to 38.59 nmol/L. It was noted 
that during the hCG therapy, there was no increase of SHBG. To the contrary, the SHBG 
concentrations even showed a slight decrease. This meant that as the result of hCG 
treatment, free and bioavailable testosterone concentrations increased. The rise was 
proportional to that in total testosterone, as was reported (Fiers & Kaufman, 1999). 
There was an average increase in free testosterone concentrations from 0.0829 ng/mL 
(1.98%) to 0.201 ng/mL (2.29%) The bio-available testosterone concentration also increased: 
− on average from 1.94 ng/mL (46.4%) to 4.71 ng /mL (53.6%). At the same time, there was 
a steady increase in the average concentration of estradiol, from 138.6 pmol/L to 280.9 
pmol/L. In paralel, the average PSA level decreased by 40% (from 3.09 ng/mL to 1.83 
ng/mL) after 37 months of therapy. These results are shown in Table 9, below. 
 
 T T-f T-ba E-2 SHBG PSA-t 
Before 18.4 0.0829 (1.98%) 1.94 (46.4 %) 138.6 35.1 3.09 
During 38.59 0.201 (2.29%) 4.71 (53.6 %) 280.9 34.86 1.83 
T= total testosterone (in nmol/L), T-f = free testosterone (in ng/mL), T-ba = bioavailable testosterone (in 
ng/mL), E-2=estradiol (in pmol/L), SHBG=sex hormone binding globulin (in nmol/L), PSA-t = total 
Prostate-Specific Antigen (in ng/mL). 
Table 9. Testosterone (total, free, bioavailable), estradiol, SHBG & PSA before and 
during/after 3 years of hCG therapy 
During LOH treatment with testosterone there was also no significant PSA increase, which 
was regarded as evidence further supporting the safety of this therapy (Wang, et al., 2009). 
But achieving a 40% reduction in PSA during the hCG therapy, with a simultaneous 
increase of more than 2-fold in serum testosterone levels as reported above show for the first 
time that the hCG therapy is not only highly effective for all age groups, but quite safe  
as well. 
There is clear evidence now that hCG therapy is safe and effective as a treatment of choice 
for men with late onset hypogonadism. During many years of continuous use of 
preparations, where hCG was the active ingredient, for LOH therapy, none of untoward 
side-effects were observed nor reported. It has also been confirmed by the files at the 
Division for Monitoring of Adverse Actions of the High Authority for Registration of Drugs 
and other Medical Products in Poland. The reports in these files have shown that in the last 
14 years there has not been any case reporting a man showing the potential side effects of 
preparations used in the treatment, in which the hCG is the active ingredient (Reports from 
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the years 1996-2009). This applies to 1200 patients treated by my and to the thousands of 
other patients treated by other physicians across Europe. 
4.2 LOH and the possibility to restore testosterone endosynthesis 
Stimulation of hormonal balance with hCG in LOH men, in most cases does increase 
endosynthesis of natural testosterone. This is true also for all age groups. In young men the 
increase can be even as high as 300%. With age, the induction of endosynthesis with hCG 
therapy gets relatively weaker, but still effective enough to eradicate manifestations of the 
Testosterone Deficiency Syndrome (TDS). The analysis of the findings of the author’s 
studies show that the opinions about the Testosterone Deficiency Syndrome etiology, so far 
reported in medical publications were erroneous. The author’s studies on the material of 908 
males treated with the hCG preparations for inducing testosterone endosynthesis, has 
proved that such induction is possible in any age group, but physiologically it diminishes 
with man’s age. (Gomuła & Rabijewski, 2010). Yet, effective endosynthesis is maintained 
until late senility, which is in the contrast to the belief that Leydig’s cells completely cease to 
function with age. In men aged 30–39 years, the mean increase of serum testosterone 
concentration resulting from hCG therapy was 128%, in those aged 40 – 49 years – 126%, in 
age group of 50 – 59 years – 129%, aged 60 – 69 years – 121%, aged 70 – 79 years – 99%, and 
in those aged 80 – 99 years it was 88%. 
A statistical analysis has revealed that the effectiveness of hCG therapy depends mainly on 
the LH/F ratio, and to a lesser extent on the patient's age (where:  LH = luteinizing hormone 
in the IU/L, and F = free PSA (expressed as free PSA/total PSA in %). 
The data showing the relationship of the decrease in the ability of testosterone 
endosynthesis with the LH/F ratio, rather than age, are provided in Table 10, below. 
 
 LH:F= 0.1 LH:F= 0.15 LH:F= 0.20 LH:F= 0.25 LH:F= 0.3 LH:F= 0.35 
30-40y 175% 160% 145% 130% 115% 100% 
40-50y 164% 149% 134% 119% 104% 89% 
50-60y 153% 138% 123% 108% 93% 78% 
60-70y 142% 127% 112% 97% 82% 67% 
70-80y 131% 110% 109% 89% 72% 52% 
80-89y 119% 98% 84% 81% 60% 41% 
Table 10. Ability of testosterone endosynthesis versus the LH/F ratio and age 
Knowing the LH/F ratio helps to predict the outcome of the hCG treatment. When the 
LH/F ratio is lower than 0.15, a patient is still able to rebuild the synthesis of endogenic 
testosterone. Once LH/F ratio increases above 0.30, a patient is much less likely to be able to 
achieve that. Another very important correlation. The serum LH and free PSA levels are 
essential for the health of prostate. In the recent studies of drugs for treatment of benign 
prostatic hyperplasia (BPH), there is an emphasis on lowering LH. For many years the 
LHRH analogues have been used to treat prostate cancer. 
When the LH/F index in a patient with late onset hypogonadism exceeds 0.5, there is an 
indication for particularly thorough detection of prostate cancer. 
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The results of my follow-up of these 1200 patients show clearly that the decrease in the 
ability of testosterone endosynthesis is synonymous with increased risk of prostate cancer. 
4.3 Late - onset hypogonadism and androversion 
The effect of HRT with exo-testosterone is that after the treatment is discontinued, the 
patient’s testosterone concentration level is lower than that which was when the treatment 
was initiated. In contrast to this, when hCG therapy is discontinued, the abilities for 
testosterone endo-synthesis are the same as they were before the treatment. Around 30% of 
patients developed a phenomenon, which can be called androversion – no need nor 
willingness to continue the hCG therapy, once an increase of 50–150% of testosterone levels 
was reached by natural endosynthesis.  
The long term hCG treatment (6-24 months) can cause permanent increase ( i.e. saturation) 
in testosterone endosynthesis, so the further induction by hCG administration will be not 
indicated. Is it possible to predict whether a man has the chance of achieving such a state of 
androversion?  The answer is still uncertain. When a man, in his initial blood tests, has a 
very high concentration of LH and low testosterone levels, the prognosis for him to reach a 
state of androversion is negative. In such cases, the thorough prostate cancer detection tests 
are highly indicated, as such a patient belongs to the high-risk group. What is more, there is 
no increased PC risk associated with the continuing of hCG therapy for such a patient. 
Importantly, however, there may be an increased risk of prostate cancer, if and when the 
hCG therapy is discontinued. In case when there is a decrease in SHBG, this indicates that 
hCG therapy can be safely discontinued. The concentrations of LH, testosterone, SHGB, E-2, 
and PSA must be measured after one month and then again after two months. If for a period 
of two months, the concentrations of testosterone are high, in excess of those in the previous 
therapy, it is the proof of the onset of androversion. Furthermore, it is the sign of the end of 
indications for further hCG treatment. The aforementioned parameters should be monitored 
every 6 months. If, after 6 months, one notices a drop in serum testosterone, it is advisable to 
renew regular hCG treatment. If, however, a low concentration of testosterone, high LH 
levels, and elevated PSA reccur in the subsequent blood tests, this should be a signal to do 
further diagnostic tests, in order to be able to exclude or to undertake measures to treat 
prostate cancer. 
4.4 Recomendation for Late - onset hypogonadism therapy – discussion  
The problem with therapy of LOH in men, is the long-standing notion that andropause is 
like mirror image of menopause. Commonly, by the term « menopause » we understand the 
period when amenorrhea sets in for many years to follow, and women may even undergo 
HRT. A rather correct term for this period of women’s life is « post-menopause ». The 
medically defined « menopause » lasts for only few months during which, the menstrual 
cycle gradually comes to a stop. This is due to the rapid decay and eventually total cessation 
of synthesis capacity of hormones in ovaries. 
In men, such a phenomenon does not take place. A man loses his hormonal capacity, fertility 
and sexuality gradually over a period of many, many years.  There are no such things in 
men, like such rapid, almost dramatic drops in concentrations of gonadal hormones. 
The official recommendations of the National Health Service of Poland for treatments of 
men with LOH, recommend the use of both:  either Testosterone or hCG therapies with no 
emphasis on either one. This well-balanced approach merits recognition.  
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Testosterone preparations − hormone replacement therapy (HRT) − are recommended in a 
series of guidelines for the LOH treatment established by the world renowned doctors and 
scientists. In their work, there is also reference to the HCG treatment: « Human chorionic 
gonadotropin (hCG) stimulates testosterone production of Leydig cells, albeit at a lower rate in 
older men, than in younger men. Since insufficient information exists about the therapeutic 
and adverse effects of hCG treatment in older men and its higher cost, this treatment cannot be 
recommended in LOH, except when fertility is an issue » (Wang, et al., 2009). 
Over the last almost 50 years there have been many studies published on the effectiveness of 
hCG to induce endosynthesis of testosterone. They showed increases of testosterone 
concentrations from 150% to over 200% resulting from hCG therapy (Gould, 1951,  Gomuła, 
2001,  Gomuła, 2002-a, Liu, et al., 2002,  Gomuła, 2007,  Gomuła & Rabijewski, 2010).  
Own prospective study of 1200 patients aged from 20 to 89 y and monitored for >10 years 
undeniably showed hCG effectiveness in inducing endosynthesis of T. In effect, the hCG-
therapy resulted in the increase of serum testosterone from a mean of 18.4 nmol/L initially, 
to mean 38.59 nmol/L during therapy (Gomuła & Rabijewski, 2010). There is clear evidence 
that hCG therapy is safe and effective as a treatment of choice for men with late onset 
hypogonadism. It has also been confirmed by the reports on file at the Division for 
Monitoring of Adverse Actions of the High Authority for Registration of Drugs and other 
Medical Products in Poland. The reports have shown that in the last 16 years there has not 
been any case reporting a man showing the potential side effects of preparations used in the 
treatment, in which the hCG is the active ingredient (Reports from the years 1996-2011).  
This applies to 1200 patients treated by me and to the thousands of other patients treated by 
other doctors across Europe. 
On the economic side, the treatment cost of LOH when using hCG is lower than the cost of 
the newly available T preparations. In the UE countries, it amounts to about 50 Euro/month. 
It is beyond any doubt that some authors of such consensus statement are aware of the 
negative impact of testosterone replacement therapy on fertility of men. They are the 
authors who published on the contraceptive action of T in men (Wallace, et al., 1993, 
Anderson & Wu, 1996, Weinbauer, et al, 2001).  
Furthermore, many peer reviewed papers, including the report from World Health 
Organization, confirmed that after up to three months of HRT with testosterone, from 40% 
to 90% male patients developed azoo-spermy or significant oligo-spermy – clearly a 
contraceptive situation - leading to a permanent pharmacological sterilization of men! 
(WHO, 1990,  Wallace, et al., 1993, Anderson & Wu, 1996, Zhang et al., 1999, Baird, 2002, 
Anderson & Waites, 2003, Si-Tian, et al., 2004).    
These facts have been known for over 20 years, but are still suppressed from information 
available to the general public. Just to the contrary, the mandatory information for 
physicians and patients attached to each box of the products, does not even mention the 
infertility/sterilization as a possible side-effect action of HRT with testosterone! Even in the 
newest-generation testosterone product ANDROTOP, the attached leaflet lists only the 
following warning: « The Androtop medication is not intended for treatment of male 
infertility or impotence.. » . 
When comparing the two facts:  
1. treatment of men with exo-applied synthetic testosterone may cause not only infertility 
but also anatomical and functional destruction of testicles and eventually leads to their 
complete atrophy including disappearance; 
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2. treatment with hCG improves functioning of testicles, with corresponding increase of 
secretion of « good », natural testosterone, the conclusion is simple:  the treatment of 
LOH with naturally secreted testosterone is better, safer and more economical then it is 
a case synthetic exo-applied testosterone! 
The superiority of the hCG treatment over the testosterone treatment has already been 
described (Gould, 1951).  
This information, however, did not receive universal recognition. Yet hCG therapy has been 
proven to be effective and safe. Moreover, as a result of testosterone treatment, permanent 
sterilization of men follows. Other risks, which mainly occur with long-term use include 
irreversible testicular atrophy. And then only successful marketing of pharmaceutical 
companies remains. Patients seem condemned to a lifetime use of testosterone. Otherwise 
their cellular metabolism drops so low that they are vulnerable to many diseases and to 
early death.  
I want to apologize to the guideline authors – some of whom are my friends − but I cannot 
accept the fact that not having conducted any studies on hCG treatment they ruled that the 
method was uncertain. They claimed that perhaps it was even dangerous. Is the lack of 
experience concerning the effects of hCG in the LOH treatment a sufficient reason to reject 
this alternative safe, effective and affordable therapy? 
5. Conclusions  
This has turned out to be the most troublesome section… 
Not because I had objective problems, no, but because of my ethical issues. 
Among the authors of LOH therapy guidelines, which were established at international 
levels, there are my long-time friends. I do not want to upset them because I strongly believe 
that what they did was acting in good faith, but I cannot exclude the fact that they had been 
insidiously stimulated by the pharmaceutical industry. Yet, the ultimate aim of a physician’s 
actions is acting for the good of a patient, so in such context, the friendship takes a second 
place. Consequently, the conclusions that are listed below are very delicate ethically but 
unambiguously to the point. 
1. There is no doubt now that testosterone deficit, which grows with age, negatively 
affects the man’s biology in its broad meaning. 
2. The own material presented in the paper allows the author to conclude that the minimal 
reference values for testosterone concentration levels, at which testosterone therapy 
should be initiated, which are accepted universally so far, are definitely too low. 
3. Introducing a therapy to increase testosterone levels only when for many years 
testosterone deficit has inflicted irreversible anatomical changes, seems to be clearly 
delayed, and is harmful for the man’s health. 
4. Applying testosterone replacement therapy to a man with LOH makes sense only when 
it is impossible to provoke the man’s own testosterone endosynthesis. If a man is still 
able to rebuild his own testosterone endosynthesis, the treatment with hCG is 
recommended, otherwise the testosterone replacement therapy will soon make him 
infertile. Moreover applying testosterone replacement therapy for a long time, will 
result in testicular atrophy.  
5. Consequently, the guidelines and recommendations on LOH treatment should be 
verified and modified as soon as possible. 
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